TPO and hematocrit: At the end of GFD administered to HT patients for 12 months by Metso et al., no significant difference was found in FT4 hormone levels of patients in the intervention group compared with controls, but anti‐TPO and anti‐Tg levels decreased (Metso et al., 2012).